Compare DRMA & ACON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DRMA | ACON |
|---|---|---|
| Founded | 2014 | 2008 |
| Country | United States | United States |
| Employees | 8 | 6 |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5M | 3.5M |
| IPO Year | N/A | N/A |
| Metric | DRMA | ACON |
|---|---|---|
| Price | $1.21 | $3.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $10.00 | ★ $23.00 |
| AVG Volume (30 Days) | ★ 1.9M | 66.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $71.77 |
| Revenue Next Year | N/A | $80.52 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.59 | $0.72 |
| 52 Week High | $7.33 | $21.31 |
| Indicator | DRMA | ACON |
|---|---|---|
| Relative Strength Index (RSI) | 41.16 | 56.06 |
| Support Level | $1.11 | $2.38 |
| Resistance Level | $2.29 | $7.84 |
| Average True Range (ATR) | 0.08 | 0.22 |
| MACD | 0.04 | 0.13 |
| Stochastic Oscillator | 39.58 | 83.96 |
Dermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. It focuses on leveraging prior clinical and technical expertise to develop OTC treatments for conditions such as acne, psoriasis, rosacea, and seborrheic dermatitis. The company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from the OTC monograph in combination with the company's Spongilla technology for patients suffering with acne. It intends to apply its Spongilla technology platform across a range of dermatologic and aesthetic skin applications, including intradermal delivery of botulinum toxin.
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.